Your browser doesn't support javascript.
loading
Rapid antibody responses to Epstein-Barr virus correlate with reduced severity of primary infection.
Geris, Jennifer M; Stancari, Arianna L; Meirhaeghe, Madeline R; Gautam, Sakhi; Cayatte, Corinne; Schmeling, David O; Okour, Malek F; Brundage, Richard C; Hayes, Gregory M; Balfour, Henry H.
Afiliación
  • Geris JM; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, USA.
  • Stancari AL; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, USA.
  • Meirhaeghe MR; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, USA.
  • Gautam S; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, USA.
  • Cayatte C; BioPharmaceuticals R&D, AstraZeneca, California, USA.
  • Schmeling DO; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, USA.
  • Okour MF; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, USA.
  • Brundage RC; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, USA.
  • Hayes GM; BioPharmaceuticals R&D, AstraZeneca, California, USA.
  • Balfour HH; Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, USA; Department of Pediatrics, University of Minnesota Medical School, Minneapolis MN 55455, USA. Electronic address: balfo001@umn.edu.
J Clin Virol ; 155: 105267, 2022 10.
Article en En | MEDLINE | ID: mdl-36007460
BACKGROUND: We investigated Epstein-Barr virus (EBV) antibody kinetics in university freshmen who developed laboratory-documented primary EBV infection during prospective studies and correlated these kinetics with disease severity. METHODS: EBV-naïve participants had blood collected periodically and sera tested for EBV-specific antibodies with line blot and enzyme immunoassays. The line blot assay contained EBNA-1, p18, p23, BZLF-1, p138, and p54 antigens; the enzyme immunoassay contained viral capsid antigen and EBNA-1. Severity of illness (SOI) was graded 0 (asymptomatic) to 6 (bedridden). Participants with maximum SOI scores 0-2 were compared with those whose maximum SOI scores were 3-6. Time to first antibody response was analyzed using the semi-parametric COX model. RESULTS: A total of 201 sera from 38 college students collected before, during, and after primary EBV infection were tested. Earlier antibody responses correlated with milder symptoms. This was most pronounced for late-developing antibodies. The median time to development of p18 IgG was significantly earlier among low-SOI participants (64 days) than high-SOI patients (119 days; P = 0.0003).). Participants with mild disease developed EBNA-1 antibodies sooner than participants with more severe disease (125 days versus >270 days; P = 0.017). Participants with mild disease also showed more rapid loss of antibodies against IgG EA p138 and p54 ≥12 weeks post-infection (P = 0.012 and P = 0.026, respectively). CONCLUSIONS: These data suggest that rapid antibody responses to EBV correlate with reduced severity of primary EBV infection.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Herpesvirus Humano 4 / Infecciones por Virus de Epstein-Barr Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Virol Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Herpesvirus Humano 4 / Infecciones por Virus de Epstein-Barr Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Virol Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos